{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"316"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"318"}],"units":"Participants"}],"title":"Post-baseline"}],"denoms":[{"counts":[{"groupId":"OG000","value":"329"}],"units":"Participants"}],"groups":[{"description":"Participants in the Global population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.","id":"OG000","title":"Atezolizumab + Bevacizumab - Global"}],"paramType":"NUMBER","populationDescription":"The Global ADA-evaluable population was defined as all participants in the Global population who received any dose of atezolizumab and who had at least one post-baseline ADA assessment.","reportingStatus":"POSTED","timeFrame":"Baseline and post-baseline on Day 1 (pre-dose) of Cycles 2, 3, 4, 8, 12, 16 (cycle length = 21 days) and treatment discontinuation visit (up to approximately 30 months)","title":"Percentage of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab in the Global Population","type":"SECONDARY","unitOfMeasure":"percentage of participants"}